The Justice Department and organizations challenging the Trump administration's marijuana rescheduling have filed a joint briefing schedule with a federal court, setting the stage for legal arguments over the historic policy shift.
Federal officials defending the rescheduling and the plaintiffs opposing it submitted their proposed timeline Friday, according to court documents. The agreement outlines when each side will present their arguments in the lawsuit seeking to halt the move from Schedule I to Schedule III.
The litigation represents one of several legal challenges to the administration's decision to downgrade cannabis under the Controlled Substances Act. Anti-cannabis groups, including Smart Approaches to Marijuana (SAM) and other prohibition advocates, filed suit shortly after the Department of Health and Human Services recommended the change last year.
The legal calendar
Under the proposed schedule, the plaintiffs will file their opening brief arguing against rescheduling, followed by the government's response defending the policy change. The timeline also includes deadlines for reply briefs and potential oral arguments, though specific dates were not immediately disclosed in the filing.
The case centers on whether the Drug Enforcement Administration properly followed administrative procedures in accepting HHS's recommendation to reschedule marijuana. Opponents argue the move violates federal law and international treaty obligations.
But the Justice Department maintains the rescheduling followed standard regulatory review processes and reflects current scientific understanding of cannabis's medical value and abuse potential.
Industry implications
Schedule III classification would provide significant tax relief to state-legal cannabis businesses currently barred from standard business deductions under IRS code 280E. Industry analysts estimate the change could save marijuana companies hundreds of millions annually in federal tax liability.
The policy shift would also ease certain research restrictions and potentially influence state-level reforms, though it would not legalize marijuana for recreational use at the federal level.
Several cannabis industry trade groups have filed amicus briefs supporting the rescheduling, arguing the current Schedule I classification—reserved for drugs with no accepted medical use—contradicts the scientific evidence and creates operational hardships for legitimate businesses.
What's next
The court will likely approve the joint briefing schedule, allowing both sides to present their full legal arguments in the coming months. A ruling could take additional time as judges review the technical administrative law questions involved.
Meanwhile, the DEA continues implementing the rescheduling process, which involves public comment periods and final rule publication. The agency has not indicated the lawsuit will delay its work.
Legal experts note that courts typically defer to agency expertise on scientific and technical matters, potentially favoring the government's position. But opponents argue procedural irregularities could provide grounds for blocking the reform.
The outcome will determine whether the most significant federal cannabis policy change in decades proceeds or faces further delays and legal obstacles.
This article is based on original reporting by www.marijuanamoment.net.
